BioVie Inc (BIVI) - שולי רווח תפעולי

Diversification of research and development for NASH and Alzheimer's disease reduces the strategic risks for BioVie Inc. (BIVI). The operational profitability of business processes confirms current financial dynamics, where the 0.00 metric serves as the target level. However, geopolitical barriers complicate raw material logistics, while litigation and the relaunch of tests create a critical liquidity shortage, exerting pressure on the company's capital.
BIVI (BioVie Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

BioVie Inc. focuses on developing innovative drugs for the therapy of neurodegenerative pathologies and liver cirrhosis, which requires significant R&D investments. This metric reflects the share of operating profit in total revenue, allowing the investor to assess cost management efficiency and the fundamental stability of the business through EBIT margin.